Durham, NC, United States of America

Michael Scott McClure

USPTO Granted Patents = 2 

Average Co-Inventor Count = 5.3

ph-index = 2

Forward Citations = 49(Granted Patents)


Company Filing History:


Years Active: 2007-2008

Loading Chart...
2 patents (USPTO):Explore Patents

Title: The Innovative Journey of Michael Scott McClure

Introduction

Michael Scott McClure is an accomplished inventor based in Durham, NC. With a strong background in chemical compounds, he holds two patents that contribute to the field of selective estrogen receptor modulation and the treatment of disorders related to aberrant erbB family PTK activity.

Latest Patents

His latest inventions include "Triphenylethylene Compounds as Selective Estrogen Receptor Modulators," which involves compounds designed for therapeutic use, specifically novel prodrugs that enhance the delivery of parent compounds for selective estrogen receptor modulation. Additionally, he has developed "Quinazoline Ditosylate Salt Compounds," which describe ditosylate salts of 4-quinazolineamines and their methods of use in treating disorders characterized by aberrant erbB family PTK activity.

Career Highlights

Throughout his career, McClure has made significant contributions to major pharmaceutical companies. He has worked at SmithKline Beecham Ltd and SmithKline Beecham Corporation, where he leveraged his expertise to develop innovative solutions in the pharmaceutical industry.

Collaborations

In his journey, McClure collaborated with notable professionals such as Martin Howard Osterhout and Frank Roschangar. These collaborations have played an essential role in advancing his research and inventions.

Conclusion

Michael Scott McClure's contributions to the field of patentable inventions underscore the importance of innovation and collaboration in science. His work continues to pave the way for new therapeutic avenues and demonstrates the profound impact of inventors on healthcare and beyond.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…